NCT06423911Phase 3Recruiting

Study of Olverembatinib (HQP1351) in Patients With CML-CP

Study sponsor: Ascentage Pharma Group Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-06-30Estimated
Enrollment · participants333Estimated
Source updated2026-09-15Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: MMR rate Part A Measure: MMR rate Part B. After: Measure: 24-Week MMR Rate (Part A) Measure: 24-Week MMR Rate (Part B).

Planned enrollment increased by 48 participants

Before: 285 participants (planned). After: 333 participants (planned).

Primary completion date changed

Before: Dec 2025. After: 30 Jun 2027.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview